Purple Biotech Ltd. (PPBT)

Purple Biotech approaches cancer therapy through a specific lens: most solid tumors defeat immunotherapy not because the patient’s immune system is weak, but because the tumor itself actively disables immunity through molecular mechanisms that existing checkpoint inhibitors do not address. The company’s pipeline centers on combating these evasion tactics—mechanisms that Purple Biotech has identified, validated, and is now testing in humans in Phase 1 and Phase 2 trials across multiple indications.

The company was founded on the observation that tumors upregulate proteins like CEACAM1 and activate signaling pathways like IRS/STAT3 to actively suppress T-cell killing and create an immunosuppressive microenvironment. Existing therapies like pembrolizumab and nivolumab—the PD-1 checkpoint inhibitors that have transformed oncology over the past decade—work by releasing the brake on T cells. But they work only if the tumor hasn’t also erected other barriers. Purple Biotech’s strategy is to hit these secondary, tumor-intrinsic evasion mechanisms in combination with checkpoint inhibitors, creating a more complete immune activation. This rationale is compelling in theory and has shown promise in early human data, but it also positions Purple Biotech in direct competition with enormously larger, more established oncology companies and with a broader field of immuno-oncology specialists.

The lead program, CM24, is a humanized monoclonal antibody that blocks CEACAM1, a surface protein that tumors use to evade immune recognition and suppress T-cell function. CM24 has been tested in combination with checkpoint inhibitors in pancreatic ductal adenocarcinoma, one of the hardest cancers to treat. In a Phase 2 trial, CM24 combined with Roche’s atezolizumab achieved a 79 percent reduction in the risk of death relative to atezolizumab alone—a remarkably large effect if it holds. Pancreatic cancer is typically highly lethal, with median overall survival measured in months, so any meaningful benefit is clinically significant. But the trial was not randomized at the outset; the comparator arm was a historical control, which introduces uncertainty into the result. A Phase 2b randomized trial is planned to begin in late 2025 to test whether the benefit reproduces in a prospective, controlled setting. If successful, CM24 would likely advance toward Phase 3, the pivotal trial required for regulatory approval. The company has also identified a potential biomarker—a blood or tumor measurement that might predict who will benefit from CM24—which could allow a narrower, higher-efficacy trial population and faster approvals.

NT219, Purple Biotech’s second major program, is a small-molecule inhibitor targeting the IRS1 and IRS2 proteins, which sit at a hub of immune-suppressive signaling in the tumor microenvironment. NT219 has been tested in Phase 1/2 trials in recurrent or metastatic head and neck cancer, in combination with pembrolizumab or cetuximab. Early data showed activity and tolerability, and the company is now advancing into a Phase 2 trial in partnership with the University of Colorado. Head and neck cancers are common, and immunotherapy-resistant head and neck cancers represent a significant unmet need, but this indication is also crowded with competitors and checkpoint inhibitors alone have limited efficacy. NT219’s edge will depend on demonstrating a meaningful survival benefit in combination, which won’t be clear until trial data matures.

The company has also disclosed a third platform, CAPTN-3, described as a multi-valent tri-specific antibody designed to engage multiple targets on the tumor and activate immune cells simultaneously. Preclinical data presented at an oncology conference in late 2025 showed activity in solid-tumor models, including some resistant to checkpoint inhibitors, but CAPTN-3 remains in early preclinical development with no clinical trials yet announced.

Purple Biotech’s competitive position is challenging for a simple reason: the immuno-oncology field has matured and become intensely crowded. The blockbuster checkpoint inhibitors—Merck’s Keytruda, Roche’s Tecentriq, Bristol Myers Squibb’s Opdivo—have enormous cash flows and enormous capabilities in clinical development, manufacturing, and commercial infrastructure. Dozens of biotech companies have launched with similar rationales: identify a mechanism of tumor immune evasion, develop a drug to block it, test it in combination with checkpoints, and hope for a regulatory win and commercial success. Some of these combination approaches have succeeded (Roche’s Tizona, a CD40 agonist, in combination with Tecentriq, is in late-stage development). Many have failed or been abandoned. The barrier to Purple Biotech’s success is not scientific insight—the hypothesis that multiple targets must be hit is sound—but rather execution: designing trials that are large enough and well-controlled enough to convince regulators that the benefit is real; manufacturing GMP-grade material at scale; navigating patent landscapes crowded with earlier filers; and ultimately, if approved, competing for adoption against entrenched incumbents.

Purple Biotech is also based in Israel, not the United States, which gives it access to excellent academic medicine and regulatory clarity, but also makes it harder to recruit patients in the competitive U.S. market and harder to build the U.S. commercial relationships that drive adoption after approval.

The path forward for Purple Biotech hinges on two pivotal data readouts: whether CM24 succeeds in the Phase 2b randomized trial for pancreatic cancer, and whether NT219 shows meaningful benefit in Phase 2 head and neck cancer. If both succeed, the company would have two clinical-stage assets in significantly different indications, which would substantially increase its value and reduce its execution risk. If one or both fail, Purple Biotech would face pressure to reprioritize or restructure. The company is also pursuing patent protection for NT219 in combination regimens across multiple geographies, which, if granted, would extend the potential commercial exclusivity window.

Investors tracking Purple Biotech should monitor clinical trial enrollment and any interim efficacy or safety data releases. Pancreatic cancer trials move slowly due to the deadly nature of the disease and the ethical imperative not to randomize patients to an inferior arm; any data release should be examined carefully for signs of efficacy, tolerability, and whether the effect size aligns with expectations. Similarly, head and neck cancer trial readouts will be critical. Patent grants or rejections in major jurisdictions (U.S., Europe, Japan) can also move the stock, because they affect the length of potential market exclusivity. Competition from other combination approaches, particularly if a competitor announces favorable data before Purple Biotech does, would materially pressure the valuation and scientific narrative.